Keeping up with the Kindlers: Merck buys Schering-Plough

Share this article:
Merck is acquiring Schering-Plough for $41.1 billion in a bid to bolster its pipeline, broaden its global presence and strengthen its specialty sales force.

The merger, the company said in a release, “will double the number of potential medicines Merck has in Phase III development” to 18, including Schering-Plough's novel thrombin receptor antagonist. The deal also strengthens Merck's commercial organization through Schering-Plough's “focus on specialty therapeutic areas and its strength in international markets.” And the merger will help Merck bump the share of its revenue generated outside the US to more than 50%, the firm said.

The combined company, to be called Merck, will be led by Merck CEO Richard Clark, who will serve as chairman, president and CEO. Schering-Plough chief Fred Hassan “is committed to continuing the strong operations at Schering-Plough and intends to participate in the integration planning until the close.” Together, Merck and Schering-Plough had revenues of $47 billion in 2008.

Merck and Schering-Plough have long partnered on a joint venture cholesterol franchise that included Zetia and Vytorin. The integration of that joint venture was cited as a prime contributor to a projected $3.5 billion annual cost savings Merck expects to reap from the merger.

Merck called retaining top talent from both organizations a key priority and expects that “the substantial majority" of Schering-Plough staff will remain at the combined company. Both companies instituted immediate hiring freezes.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...